Researchers have developed a novel proteogenomic tumor map that identifies a high-risk subset of diffuse large B-cell lymphoma patients who are unlikely to respond to standard chemotherapy and antibody regimens. The study, published in Cancer Cell, addresses a critical challenge in treating the disease, which accounts for more than 150,000 new cases globally each year. While standard therapies such as R-CHOP or Pola-R-CHP successfully cure nearly two-thirds of patients, over a third experience relapse or primary resistance due to the molecular heterogeneity of the cancer. To overcome the limitations of existing genetic classification systems, an international research consortium led by institutions in Frankfurt analyzed tumor samples from 478 individuals. The team integrated genetic sequencing, proteomic profiling, and interpretable machine learning models to correlate molecular patterns with clinical outcomes. This multi-layered approach revealed that different genetic mutations can converge into similar functional tumor phenotypes, a relationship previously obscured by traditional diagnostic methods. The analysis identified a distinct high-risk molecular profile designated PG4. Tumors within this subgroup are characterized by overactivity of the MYC oncogene, which drives rapid cell proliferation, and a severely immunosuppressed microenvironment. Specifically, the tumor niche lacks cytotoxic T cells and actively suppresses their function, rendering the cancers immunologically cold and resistant to standard treatments. These biological markers operate independently of conventional risk factors, providing a more precise method for identifying patients who require immediate alternative interventions such as CAR T-cell therapy. Preclinical experiments validated the clinical findings by demonstrating that targeted pharmacological inhibition of MYC-driven signaling pathways selectively eliminated PG4 lymphoma cells in laboratory cultures. This discovery establishes a clear, actionable therapeutic target and lays the groundwork for precision diagnostics tailored to specific proteogenomic profiles. The integration of artificial intelligence with high-resolution single-cell tumor mapping marks a significant advancement in hematologic oncology. By translating complex multi-omics data into clinically interpretable risk categories, the research framework enables earlier identification of treatment-resistant cases and supports the development of customized therapeutic strategies. Researchers anticipate that these findings will eventually refine standard protocols for aggressive lymphomas and accelerate the transition toward biology-driven treatment pathways.